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Abstract 
Background 
Atrio-oesophageal fistula was first reported as a fatal complication of surgical endocardial 
and percutaneous endocardial radiofrequency ablation for atrial fibrillation, with an incidence 
after catheter ablation between 0.03% and 0.5%. Magnetic resonance angiography (MRA) 
was usually performed to obtain pre-procedural 3D images, used to merging into an electro-
anatomical map, guiding step-by-step ablation strategy of AF. Our aim was to find an easy, 
safe and cost-effective way to enhance the oesophagus during MRA. 
Methods 
In 105 consecutive patients, a right-left phase encoding, free breathing, 3D T1 MRA 
sequence was performed in the axial plane, >24 hours before catheter ablation, using an 
intravenous injection of gadobenate dimeglumine contrast medium. The oesophagus was 
enhanced using an oral gel solution of 0.7 mL gadobenate dimeglumine contrast medium 
mixed with approximately 40 mg thickened water gel, which was swallowed by the patients 
on the scanning table, immediately before the MRA sequence acquisition. 
Results 
The visualisation of the oesophagus was obtained in 104/105 patients and images were 
successfully merged, as left atrium and pulmonary veins, into an electro-anatomical map, 
during percutaneous endocardial radiofrequency ablation. All patients tolerated the study 
protocol and no immediate or late complication was observed with the oral contrast agent 
administration. The free-breathing MRA sequence used in our protocol took 7 seconds longer 
than MRA breath-hold conventional sequence. 
Conclusion 
Oesophagus visualization with oral gadobenate dimeglumine is feasible for integration of 
oesophagus anatomy images into the electro-anatomical map during AF ablation, without 
undesirable side effects and without significantly increasing cost or examination time. 
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Background 
Atrio-oesophageal fistulae were first reported as a fatal complication of endocardial surgical 
radiofrequency (RF) ablation for atrial fibrillation (AF) [1], and have since been reported 
after percutaneous endocardial RF catheter ablation (RFCA) [2,3]. The incidence of atrio-
oesophageal fistula after catheter ablation was estimated at 0.03–0.5% [4,5] and associated 
with high mortality rates [6], even when the correct diagnosis was made relatively early in the 
clinical course. Atrio-oesophageal fistula after catheter ablation is caused by heat transfer to 
the oesophagus [7], which causes transmural tissue necrosis [8], mediastinitis, and a fistulous 
connection between the oesophageal lumen and the left atrial blood pool. Thus, prevention of 
the initial oesophageal injury during the ablation procedure is important if the development of 
atrio-oesophageal fistula is to be avoided. 
Any strategy to limit or avoid RF energy delivery in close proximity to the oesophagus 
requires that the clinician have accurate information regarding the anatomy since the 
oesophagus is anatomically close to the left atrium (LA). However, the anatomical 
relationship between the oesophagus and the LA is highly variable [9,10]. In 15% of patients, 
minor oesophageal lesions have been detected as ulcerations by endoscopy [11]. Moreover, 
cardiac magnetic resonance angiography (MRA) or computed tomography (CT)-angiography 
(CTA) are often performed to obtain pre-procedural three-dimensional (3D) images of the 
anatomy of the LA and pulmonary veins (PVs) before the RFCA procedure. The electro-
anatomical map was then integrated with 3D images of MRA or CTA to create a map that 
provides a step-by-step ablation strategy for AF. 
The purpose of this study was to assess oesophageal anatomy and position prior to MRA 
using a technique that integrates an electro-anatomical map during the RFCA procedure. 
Methods 
This study included 105 consecutive patients with AF (92 males, 13 females, mean age 55.2 
years) that were candidates for RFCA (Table 1). Three patients suffered from mild achalasia 
due to neurological complications. In all patients MRA was performed within 24 h before 
catheter ablation using gadobenate dimeglumine contrast medium (Gd-Bopta, Multihance, 
Bracco Altana Pharma, Constance, Germany) for intravenous and oral administration. We 
collected informed consent for the MR examination and for oral administration of the 
contrast medium and our study design followed Declaration of Helsinki recommendations. 
After the MR examination, all patients were clinically monitored for 30 min before being 
returned to the cardiology department. Any adverse effects or anomalies were registered after 
RCFA prior to discharge. 
Table 1 Patients characteristics 
 Men Women 
Number of Patients 92 13 
Age (years) 58,5 (42 to 70) 52,6 (39 to 69) 
Paroxistic Atrial Fibrillation 70 (76%) 9 (70%) 
Persitent Atrial Fibrillation 22 (24%) 4 (30%) 
Duration of Atrial Fibrillation (years) 6.4 6.1 
MRA study protocol 
We used a 1.5-Tesla Magnet (Philips Medical Systems, DA Best, Netherlands) with a cardiac 
coil volumetric phased array consisting of 32 elements from a rigid rear portion and a flexible 
front, each consisting of a 16-channel phased array. MRA was performed in the axial plane 
with a non-ECG-gated, breath-free sequence, Spoiled Gradient Eco 3D (TR 3–8 ms, TE 1–3 
ms), with R-L phase encoding, using a FOV of 450 mm, 512 × 512 matrix with an isotropic 
voxel of 1.5 mm and flip angle of 20°. The mean sequence time was 25 s (range, 19–32 s). 
The acquisition was performed after intravenous infusion of gadobenate dimeglumine 
contrast agent (infusion rate = 2.5 ml/sec; 0,05 mmol*kg), followed by a 20-ml saline bolus. 
Bolus tracking was used to start the sequence at the exact moment at which the contrast 
intensified during the venous phase of pulmonary circulation to guarantee the maximum 
signal intensity in the PVs and into the LA. 
The oesophagus was intensified by administration of a 0.7–0.8-ml gel solution of gadobenate 
dimeglumine contrast media mixed with ~40-mg thickened water gel (Nestlé Healthcare 
Nutrition SA, Barcelona, Spain), served with a disposable plastic spoon, while the patients 
were on the scanning table immediately before MRA sequence acquisition. The patients were 
previously instructed to swallow the bolus 2–3 s before starting the MRA sequence. A 
second-pass MRA sequence was acquired immediately after with the same first-pass settings 
to obtain suitable images in case of initial technical problems. During post-processing, LA 
volume and left appendage volume were calculated by locating the regions of interest, while 
3D MIP and 3D volume rendering reconstruction was performed to assess the spatial position 
of the oesophagus and identify appendage morphology and any PV anatomical variations. 
Results 
Our technique was tested initially on a healthy volunteer to demonstrate feasibility and 
predict problems during the MR examination following gel administration. During the study, 
all patients tolerated the study protocol and no immediate or late complication was observed 
after administration of the oral contrast agent. The oesophagus was visualised and 
successfully merged into the electro-anatomical maps in 104/105 patients (Figure 1; Figure 
2). One patient did not swallow the bolus because he did not hear our instruction to do so. We 
obtained a fully enhanced oesophagus in 100/104 patients (96%). In four patients, the 
oesophagus was not enhanced completely (Figure 3), due to peristaltic waves, but images 
were merged in an electro-anatomical map without difficulties. The breath-free MRA 
acquisition time, with double contrast agent administration using R-L phase encoding, was a 
mean of 7 s greater (range 5–12 s) than with the breath-hold MRA GRE-T1 breath-hold 
sequence without oral administration of contrast medium. No technical problems were 
encountered during first- or second-pass imaging. 
Figure 1 MRA of a 66 years old male with AF. MIP reconstruction in post-processing of 
MRA images acquired using both venous and oral Gadobenate Dimeglumine, 24 hr before 
percutaneous catheter ablation: (a) Axial MIP reconstruction (b) Left sagittal 3D MIP 
reconstruction (c) Left-Posterior 3D MIP reconstruction. 
Figure 2 Same Patient. MRA images and Electro-anatomical map 3D merging. On top line: 
3D volume rendering from 3D GRE T1 scan; on bottom line: CARTO-MERGEtm map using 
MRA examination data during RFCA procedure; (a) Posterior Coronal (b) Left-Posterior 
oblique (c) Left Sagittal. 
Figure 3 MRA of a 56 years old male, suffering AF. 3D volume rendering from 3D GRE 
T1 scan, showing the incomplete filling of the oesophagus (white arrow), due to a peristaltic 
wave. 
Discussion 
Oesophageal injury is a rare but serious complication of RFCA. The oesophagus is positioned 
relative to the LA, adjacent to the right antra and ostia PV, as well as the posterior LA 
between the right and left PVs, or the left PV antra and ostia [12-15]. However, the position 
of the oesophagus is variable. Thus, the oesophagus could be at risk of thermal injury during 
RF ablation from virtually anywhere at the posterior left atrial endocardium or within the PV 
near the ostia, depending on the anatomy of the individual patient. 
CTA and MRA are now the standard reference imaging techniques for LA and PVs. Volume 
rendering images obtained by these methods are merged on an electro-anatomical map 
generated with Carto™ (Biosense Webster, Diamond Bar, CA, USA) or NavX™ (St. Jude 
Medical, Sylmar, CA, USA) to guide catheter ablation. A report by Bahnson categorised the 
imaging methods to define the oesophagus-atrium relationship into real-time methods, 
including trans-oesophageal ultrasounds, nasogastric tube and barium paste, that yield images 
during RF-energy delivery; and non-real-time methods, including CT and MR, that yield 
static images generated prior to RF energy delivery. 
Ultrasound is the only real-time imaging modality that allows visualisation of the extent or 
thickness of the oesophagus wall. However, this is an invasive imaging technique that 
requires operator experience. Placement of a nasogastric tube to allow oesophageal location 
mapping is associated with some risk of trauma and bleeding, particularly for anti-
coagulation. Barium paste can be used to visualise the true width of the lumen for a few 
seconds, although information regarding oesophageal wall thickness is difficult to infer as 
only the lumen is visualised [16]. 
Real-time methods are more reliable for identification of oesophageal anatomy during RFCA 
than non-real-time methods. Kobza et al. performed a CT study using a common gastric tube 
as a marker the day before RFCA, and reported that the position of the oesophagus relative to 
the LA was dynamic and did not correspond to the position reported in the pre-procedural 
study [17]. Further, when the oesophageal position was defined by a pre-procedure CT scan 
with barium paste or by post-processing tagging and compared with the intra-procedure 
position defined using an electro-anatomical mapping system, in 85% of cases the position of 
the oesophagus corresponded to that identified with the CT scan performed <48 h prior 
[18,19]. This could be explained by a thin gastric tube placed on the side of the oesophagus. 
Our study demonstrates that a bolus better represents the true anatomical shape and size of 
the oesophagus. 
Pavone et al. first performed a MR scan with barium paste and the MR contract agent, 
gadopentetate dimeglumine, to visualise the oesophageal lumen in patients with oesophageal 
stenosis [20]. MRA, besides providing detailed and complete imaging of the complex LA 
anatomy, does not expose the patient to ionising radiation [21]. Pollak et al. performed MRA 
with barium paste and gadopentetate dimeglumine in four candidates for RFCA; in one 
patient, the contrast agent passed to the stomach without enabling visualisation of the 
oesophagus [22]. A MRA scan is usually of longer duration than CT, and swallowing a 
contrast medium bolus at the correct time during a long breath-hold period could be difficult 
for the patient. In this study, using R-L phase encoding the patient could breathe freely and 
swallow the bolus during the MRA sequence without creating artefacts or affecting image 
quality. Although no technical problem was encountered with the first-pass MRA sequence, 
performing a second-pass immediately after the first MRA sequence could be useful for 
obtaining images suitable for anatomical assessment and calculating LA volume. With the 
second-pass MRA, we demonstrated that the contrast media and gel bolus rapidly pass 
through the oesophagus into the stomach, even in achalasic patients, without atrial wall 
artefacts, permitting fibrosis quantification associated with the likelihood of recurrent 
arrhythmia [23]. 
Allgayer et al. [24] reported that many MR protocols use atrial imaging to assess the anatomy 
and merge 3D images with an electro-anatomical map. However, only 3D-ECG-gated MRA 
allowed collection of the necessary anatomical information with optimal quality, although the 
acquisition time was >10 min. This study determined that the optimum solution for quality 
and patient tolerability was use of 3D MRA breath-hold non-ECG gated to assess the atrial 
anatomy necessary to merge the electro-anatomical map and 2D T2 axial images used to 
evaluate the theoretical position of the oesophagus. The MRA breath-free sequence used a 
comparable acquisition time to obtain 3D images of the atrium and oesophagus that could be 
merged into an electro-anatomical map. 
Previous studies have reported that diluted gadolinium (Gd) complexes are safe for use as 
oral gastrointestinal contrast agents [25,26]. A Gd-BOPTA formulation was used in the 
present study because its signal intensity in T1-weighted images is greater than that of 
gadopentetate dimeglumine with increasing T1 relaxation times and dose. In human plasma, 
gadobenate dimeglumine is more effective in terms of shortening T1 relaxation times [27]. 
MR colonography is used in the gastrointestinal tract for faecal tagging because it is partly 
excreted in bile. Furthermore, the C-functionalised compound gadobenate dimeglumine 
exhibits high transmetallation towards metallic ions, such as Zn2+, and a long half-life 
dissociation in a strong hydrochloric acid (pH = 1) [28]. In addition, a study demonstrated 
that 99.2% of orally administered gadolinium contrast medium was excreted in the faeces and 
not absorbed [29]. In our study, we reported that the novel use of gadolinium-based contrast 
agent without barium paste allowed oesophageal enhancement during MRA. Furthermore, 
thickened gel water, which is often used when feeding weak and critical patients [30], could 
be used safely in patients suffering from a swallowing dysfunction and airway problems. 
Moreover, unlike barium, it is gluten, lactose, sugar and allergy free. Barium sulphate is also 
more costly than thickened water gel (2.18 € vs. ~0.60 €       	
 
	 
ml of gadopentetate dimeglumine is priced similarly to gadobenate dimeglumine (5.7€ vs. 
5.9€  
Conclusions 
Oesophagus visualisation with oral administration of gadobenate dimeglumine MRA is a 
feasible technique without side effects and without significant increase in cost or examination 
time. Three-dimensional images obtained can be successfully merged during RFCA to 
characterise LA, PVs and oesophageal anatomy. Integration of oesophageal images into the 
electro-anatomical LA map could help to prevent RFCA injury to the oesophagus. 
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